Becton, Dickinson and Company (BDX)
Medical device maker Becton Dickinson cuts 2025 profit forecast on potential tariff hit
Medical device maker Becton Dickinson lowered its annual profit forecast on Thursday, in anticipation of a potential hit from U.S. President Donald Trump's tariffs, sending its shares down 5% in premarket trading.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Gear Up for Becton Dickinson (BDX) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Becton, Dickinson and Company: It's Wait And See For Me
Becton, Dickinson and Company is a leading medical device firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. BDX operates in three segments: BD Medical, BD Life Sciences, and BD Interventional, with plans to spin off its Biosciences and Diagnostic Solutions business in 2026. BDX has struggled over the past decade, with a 10-year CAGR of only 5.1%.
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
DGI For The DIY: 2024 Dividend Portfolio Review
This portfolio focuses on generating a growing stream of dividend income by investing in companies that consistently increase dividends. I reinvest dividends into more shares of the companies I already own to compound growth. The investment strategy is guided by specific principles to ensure consistent and disciplined investing.
BD Seeks Potential Buyers for Life Sciences Business Division
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
Becton Dickinson in talks to divest life sciences unit, FT reports
Medical device maker Becton Dickinson has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific and Danaher , the Financial Times reported on Tuesday.
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipeline. The firm is a proven dividend grower and cashflow generator with low debt/equity and investment-grade credit ratings.
BDX Stock Declines Following Class I Classification for Alaris Recall
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
